ROCKET PHARMACEUTICALS INC (RCKT) Stock News

USA - NASDAQ:RCKT - US77313F1066 - Common Stock

3.71 USD

-0.29 (-7.25%)

Last: 10/17/2025, 8:00:01 PM

3.8393 USD

+0.13 (+3.49%)

After Hours: 10/17/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RCKT Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Benzinga

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock

5 days ago - By: Benzinga - Mentions: ERIC ACI DPZ JPM ...

Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday

5 days ago - By: Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

2 months ago - By: Stocktwits

Why Is Rocket Pharma Stock Up 15% Pre-Market Today?

9 days ago - By: Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 days ago - By: Stocktwits - Mentions: IWMW ESGV

Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy

a month ago - By: Kuehn Law, PLLC

Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm

2 months ago - By: Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

2 months ago - By: Zacks Investment Research - Mentions: AMRN AKRO ALGS

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

2 months ago - By: Stocktwits - Mentions: SRPT

Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients

2 months ago - By: Faruqi & Faruqi, LLP

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

2 months ago - By: The Gross Law Firm

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact The Gross Law Firm

2 months ago - By: THE ROSEN LAW FIRM, P. A.

RCKT Deadline: RCKT Investors with Losses in Excess of $100K Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

2 months ago - By: Faruqi & Faruqi, LLP

Faruqi & Faruqi Reminds Rocket Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT

2 months ago - By: Berger Montague

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

2 months ago - By: The Law Offices of Frank R. Cruz

Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

2 months ago - By: Levi & Korsinsky, LLP

August 11, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RCKT

2 months ago - By: The Motley Fool

Rocket (RCKT) Q2 Loss Narrows 16%

2 months ago - By: Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

2 months ago - By: The Rosen Law Firm PA

RCKT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT

2 months ago - By: The Gross Law Firm

Lost Money on Rocket Pharmaceuticals, Inc.(RCKT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

2 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT